<DOC>
	<DOCNO>NCT00290706</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , work different way stop growth cancer cell , either kill cell stop dividing . Bortezomib may stop growth cancer cell block enzymes need cell growth . Giving gemcitabine together bortezomib may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose bortezomib give together gemcitabine see well work treat patient relapsed refractory B-cell T-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>A Phase I/II Trial VELCADE &amp; Gemcitabine Patients With Relapsed Refractory Aggressive B- T-cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate ( complete partial remission ) patient relapse refractory aggressive B- T-cell non-Hodgkin 's lymphoma treat gemcitabine hydrochloride bortezomib . - Determine maximum tolerate dose bortezomib administer gemcitabine hydrochloride patient . Secondary - Determine time treatment failure , duration response , overall survival patient treat regimen . - Determine safety tolerability regimen patient . OUTLINE : This phase I , dose-escalation study bortezomib follow phase II , open-label study . - Phase I : Patients receive gemcitabine hydrochloride IV 30 minute bortezomib IV 3-5 second day 1 8 . Treatment repeat every 21 day 9 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 3 6 patient experience dose-limiting toxicity ( DLT ) OR dose 2 6 patient experience DLT . - Phase II : Patients receive gemcitabine hydrochloride bortezomib phase I MTD . After completion study therapy , patient follow periodically 3 year . PROJECTED ACCRUAL : A total 37 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis B Tcell nonHodgkin 's lymphoma ( NHL ) Intermediate histology Bcell NHL , include follow : Diffuse large Bcell lymphoma Transformed large cell lymphoma Any Tcell NHL histology Cutaneous Tcell lymphoma ( CTCL ) mycosis fungoides ( MF ) allow Relapsed refractory disease , define disease progress prior complete remission ( CR ) , partial remission ( PR ) , stable disease ( SD ) last therapy OR failure achieve CR , PR , SD completion last therapy Must receive 13 prior therapeutic regimen Cyclophosphamide , doxorubicin hydrochloride , vincristine , prednisone ( CHOP ) AND cyclophosphamide , vincristine , prednisone ( CVP ) OR CHOP rituximab ( CHOPR ) AND CVP rituximab ( CVPR ) consider 1 regimen Monoclonal antibody ( e.g. , rituximab ) give maintenance therapy consider 1 regimen Salvage chemotherapy follow autologous stem cell transplant consider 1 regimen No 7 prior therapeutic regimen patient CTCL MF No mantle cell lymphoma PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 3 month Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 At least 50,000/mm^3 document bone marrow involvement Hemoglobin ≥ 8.0 g/dL AST ALT ≤ 3 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 3 time ULN Bilirubin ≤ 2 time ULN Creatinine ≤ 2.0 mg/dL No known history HIV infection No active infection No uncontrolled hypertension No peripheral neuropathy ≥ grade 2 within past 2 week No myocardial infarction within past 6 month No New York Heart Association class III IV heart failure No uncontrolled angina No severe uncontrolled ventricular arrhythmia No acute ischemia active conduction system abnormality ECG No hypersensitivity bortezomib , boron , mannitol Not pregnant nursing Negative pregnancy test Fertile patient must use effective barriermethod contraception No serious medical psychiatric illness would preclude study participation PRIOR CONCURRENT THERAPY : Prior autologous and/or allogeneic stem cell transplantation allow More 3 week since prior chemotherapy , radiotherapy , immunotherapy More 3 week since prior systemic biologic anticancer therapy More 3 week since prior systemic corticosteroid ( e.g. , oral prednisone &gt; 10 mg per day ) More 2 week since prior investigational drug No prior bortezomib gemcitabine hydrochloride No concurrent systemic cytotoxic chemotherapy investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
</DOC>